Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $312M | $167M | $163M | $173M | 40.2% | 617.0% | -1009.4% |
| 2024 | $43M | $-19M | $-18M | $-51M | -21.2% | - | -61.3% |
| 2023 | $0M | $-46M | $-46M | $-39M | -66.1% | -100.0% | 56.0% |
| 2022 | $0M | $-30M | $-30M | $-25M | -53.9% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 311.71 |
| Operating Revenue | 311.71 |
| Cost Of Revenue | 35.96 |
| Gross Profit | 275.75 |
| Operating Expense | 125.61 |
| Research And Development | 19.33 |
| Selling General And Administration | 106.27 |
| Total Expenses | 161.57 |
| Operating Income | 150.14 |
| Total Operating Income As Reported | 150.14 |
| EBITDA | 167.35 |
| Normalized EBITDA | 168.54 |
| EBIT | 152.80 |
| Interest Income | 3.85 |
| Interest Expense | 2.78 |
| Net Interest Income | 1.06 |
| Other Non Operating Income Expenses | - |
| Other Income Expense | -1.19 |
| Interest Income Non Operating | 3.85 |
| Interest Expense Non Operating | 2.78 |
| Net Non Operating Interest Income Expense | 1.06 |
| Pretax Income | 150.02 |
| Tax Provision | -13.04 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | -0.25 |
| Net Income Continuous Operations | 163.06 |
| Net Income From Continuing And Discontinued Operation | 163.06 |
| Net Income From Continuing Operation Net Minority Interest | 163.06 |
| Net Income | 163.06 |
| Net Income Common Stockholders | 162.07 |
| Net Income Including Noncontrolling Interests | 163.06 |
| Normalized Income | 163.99 |
| Diluted NI Availto Com Stockholders | 162.07 |
| Basic Average Shares | 72.03 |
| Diluted Average Shares | 80.31 |
| Reconciled Depreciation | 14.55 |
| Reconciled Cost Of Revenue | 35.96 |
| Total Unusual Items | -1.19 |
| Total Unusual Items Excluding Goodwill | -1.19 |
| Special Income Charges | -6.50 |
| Restructuring And Mergern Acquisition | 6.50 |
| Gain On Sale Of Security | 5.31 |
| General And Administrative Expense | 68.22 |
| Other Gand A | 68.22 |
| Selling And Marketing Expense | 38.05 |
| Otherunder Preferred Stock Dividend | 0.99 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| CorMedix Inc.this co. | CRMD | $670M | 4.13 | 1.65 | 40.0% | 4.01 |
| Allogene Therapeutics, Inc. | ALLO | $704M | -3.69 | 2.41 | -65.3% | -4.15 |
| Aura Biosciences, Inc. | AURA | $703M | -6.62 | 5.13 | -77.6% | -5.92 |
| Candel Therapeutics, Inc. | CADL | $679M | -17.79 | 13.08 | -73.5% | -17.28 |
| Design Therapeutics, Inc. | DSGN | $672M |
| - |
| - |
| - |
| - |
| -9.63 |
| 3.16 |
| -32.8% |
| -8.33 |
| Zevra Therapeutics, Inc. | ZVRA | $660M | 7.93 | 4.27 | 53.8% | 6.70 |
| SI-BONE, Inc. | SIBN | $660M | - | 3.72 | -10.6% | - |
| Aclaris Therapeutics, Inc. | ACRS | $658M | -10.13 | 6.38 | -63.0% | - |
| Castle Biosciences, Inc. | CSTL | $655M | -27.12 | 1.39 | -5.1% | 50.72 |
| Peer Median | - | -9.63 | 3.99 | -47.9% | -5.03 | |